Acoltremon ophthalmic solution 0.003%
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Acoltremon ophthalmic solution 0.003%, covering 2026-03-31 to 2026-03-31. Get the full timeline:
Most recent: Clinical Trial Update: Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency [Phase 4]